Skip to main content
Premium Trial:

Request an Annual Quote

PPD Reported Strong Q3 Revenue, Net Profit Growth

NEW YORK, Oct. 16 - PPD said that strong revenue growth in the third quarter surpassed a mild up tick in R&D spending, helping to drive a surge in net profits.

 

For the period ended Sept. 30, PPD said total revenue were $157.3 million, up from $115.8 million one year ago. R&D in the quarter increased to just under $3 million from 1.4 million year over year.

 

As a result, the company said that net profits in the third quarter 2002 climbed to $18.3 million, or $.33 per share, from $11.5 million, or $.22 per share, in the same quarter one year ago.

 

PPD said it had around $147 million in cash and cash equivalents as of Sept. 30.

 

Click here for more information.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.